.Charles Baum, M.D., Ph.D., that managed Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2013, is taking the reins of younger biotech Terremoto Biosciences.Baum's "substantial expertise in medicine growth, and tried and tested record earlier high-impact medications, will definitely contribute," outward bound chief executive officer Peter Thompson, M.D., said in a July 25 launch. Thompson will retain his seat as panel chairperson..Baum, an experienced physician-scientist, was actually the owner, president and also chief executive officer of oncology-focused Mirati. Just before that, he aided build cancer medications at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will act as CEO at Terremoto, a provider establishing tiny molecules to target disease-causing proteins-- like those found in harmful growth cells-- using covalent bonds. Existing therapies that use covalent connects predominantly target the amino acid cysteine. Nonetheless, of the 20 amino acids that compose proteins, cysteine is the least popular. Terremoto is actually rather targeting some of the vital amino acids, amino acid lysine, which is found in nearly all healthy proteins.Through targeting amino acid lysine as well as other amino acids, Terremoto wants to deal with earlier undruggable ailments and create first-in-class medicines..The biotech, located in South San Francisco, brought up $75 million in collection A funding in 2022. A little bit of more than a year later on, the biotech greater than increased that variety in a $175 million set B.